Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 12
1979 24
1980 28
1981 25
1982 32
1983 46
1984 34
1985 37
1986 28
1987 29
1988 33
1989 35
1990 34
1991 35
1992 33
1993 43
1994 42
1995 49
1996 63
1997 63
1998 54
1999 51
2000 47
2001 59
2002 42
2003 48
2004 50
2005 43
2006 32
2007 4
2008 2
2009 4
2010 11
2011 12
2012 16
2013 4
2014 21
2015 39
2016 40
2017 69
2018 108
2019 136
2020 136
2021 177
2022 158
2023 147
2024 111

Text availability

Article attribute

Article type

Publication date

Search Results

2,207 results

Results by year

Filters applied: . Clear all
Page 1
Safety of Semaglutide.
Smits MM, Van Raalte DH. Smits MM, et al. Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34305810 Free PMC article. Review.
Tirzepatide Once Weekly for the Treatment of Obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Jastreboff AM, et al. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35658024 Clinical Trial.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Frías JP, et al. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. N Engl J Med. 2021. PMID: 34170647 Clinical Trial.
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Rubino D, et al. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. JAMA. 2021. PMID: 33755728 Free PMC article. Clinical Trial.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Wilding JPH, et al. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. N Engl J Med. 2021. PMID: 33567185 Clinical Trial.
Glucagon-like peptide agonists: A prospective review.
Mariam Z, Niazi SK. Mariam Z, et al. Endocrinol Diabetes Metab. 2024 Jan;7(1):e462. doi: 10.1002/edm2.462. Epub 2023 Dec 14. Endocrinol Diabetes Metab. 2024. PMID: 38093651 Free PMC article. Review.
Semaglutide for the treatment of obesity.
Chao AM, Tronieri JS, Amaro A, Wadden TA. Chao AM, et al. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. Trends Cardiovasc Med. 2023. PMID: 34942372 Free PMC article. Review.
2,207 results